EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren’s Disease and Association with Patient-Reported Outcomes

Jacques-Eric Gottenberg, Raphaele Seror, Nicola Massey, Megan Hughes, Victoria Barton, Sarah Weatherby, Federico Zazzetti, Andras Borsi, Wim Noel, Harman Dhatt, Angelina Villasis-Keever, Anna Sheahan und 1 weitere

Rheumatology and Therapy · 2025-12 · 12 (6) · 1083-1101

DOI: 10.1007/s40744-025-00792-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 23.09.2025. Verfasst von Jacques-Eric Gottenberg und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, National Reference Centre for Rare Systemic Autoimmune Diseases, IBMC UPR3572, CNRS, Strasbourg University Hospital, Stra…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Sjögren's disease (SjD) is often characterized by the presence of anti-SSA/Ro and anti-SSB/La autoantibodies. The Clinical European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ClinESSDAI) and Patient-Reported Index (ESSPRI) assess disease activity and patient-reported symptomatology; however, their association with patient-reported outcome measures (PROMs) remains unclear. We aimed to describe systemic disease activity in seropositive and seronegative SjD patients and evaluate the association between proxy ClinESSDAI and ESSPRI scores with PROMs. METHODS: Data were drawn from the Adelphi Real World SjD Disease Specific Programme™, a cross-sectional survey conducted in France, Germany, Italy, Spain and the United States between June and October 2018. Physicians reported patient demographics and clinical characteristics. Patients completed the EQ-5D-3L and Visual Analogue Scale (EQ-VAS), and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F). Proxy ClinESSDAI and ESSPRI scores were calculated using physician-reported organ activity and averaged patient ratings of dryness, pain, and fatigue, respectively. Associations between ClinESSDAI, ESSPRI, physician-reported disease severity, and PROMs were determined using linear and logistic regression modeling. Statistical significance was p < 0.05 for all tests. RESULTS: Overall, 319 rheumatologists provided data on 1879 patients with SjD. Mean (standard deviation) patient age was 53.2 (12.2) years, 89% were female, and 89% were White. Of patients who received serum antibody testing for both anti-SSA/Ro and anti-SSB/La antibodies (n = 1344), 69% were double seropositive and 6% were double seronegative. The most common symptoms experienced by double seropositive and double seronegative SjD patients, respectively, included dry eyes (94% and 74%), and physical fatigue (82% and 60%). ClinESSDAI and ESSPRI were significantly associated with EQ-5D-3L, EQ-VAS, and FACIT-F (all p < 0.001). CONCLUSIONS: Systemic disease activity and patient-reported symptomatology were significantly associated with health-related quality of life measures, highlighting the need for disease management that considers both clinical outcomes and the patient experience.

Schlagwörter

Stichwörter der Autor:innen

Anti-SSA/RoAnti-SSB/LaAutoantibodiesClinESSDAIESSPRIPROMsRWESjögren’s disease

Autor:innen und Institutionen

  • Department of Rheumatology, National Reference Centre for Rare Systemic Autoimmune Diseases, IBMC UPR3572, CNRS, Strasbourg University Hospital, Strasbourg, France.
  • Rheumatology, Hôpitaux Universitaires Paris- Sud, Assistance Publique Hopitaux de Paris (APHP), National Reference Centre for Rare Auto-Immune Diseases, Le Kremlin Bicêtre, France.
  • Adelphi Real World, Bollington, UK.
  • Adelphi Real World, Bollington, UK. vicky.barton@adelphigroup.com.
  • Johnson & Johnson Innovative Medicine, Spring House, PA, USA.
  • Johnson & Johnson Innovative Medicine, Beerse, Belgium.

Förderung

  • Johnson & Johnson

Zitieren

APA

Gottenberg, J. E., Seror, R., Massey, N., Hughes, M., Barton, V., Weatherby, S., Zazzetti, F., Borsi, A., Noel, W., Dhatt, H., Villasis-Keever, A., Sheahan, A., & Sbarigia, U. (2025). Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren’s Disease and Association with Patient-Reported Outcomes. Rheumatology and Therapy, 12(6), 1083-1101. https://doi.org/10.1007/s40744-025-00792-4

Vancouver

Gottenberg JE, Seror R, Massey N, Hughes M, Barton V, Weatherby S, et al. Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren’s Disease and Association with Patient-Reported Outcomes. Rheumatology and Therapy. 2025;12(6):1083-1101. doi:10.1007/s40744-025-00792-4

BibTeX
@article{Gottenberg2025,
  author = {Gottenberg, Jacques-Eric and Seror, Raphaele and Massey, Nicola and Hughes, Megan and Barton, Victoria and Weatherby, Sarah and Zazzetti, Federico and Borsi, Andras and Noel, Wim and Dhatt, Harman and Villasis-Keever, Angelina and Sheahan, Anna and Sbarigia, Urbano},
  title = {Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren’s Disease and Association with Patient-Reported Outcomes},
  journal = {Rheumatology and Therapy},
  year = {2025},
  volume = {12},
  number = {6},
  pages = {1083--1101},
  doi = {10.1007/s40744-025-00792-4}
}
Kostenlos starten →